---
title: "SLXN.US (SLXN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SLXN.US/news.md"
symbol: "SLXN.US"
name: "SLXN.US"
parent: "https://longbridge.com/en/quote/SLXN.US.md"
datetime: "2026-06-13T13:52:39.203Z"
locales:
  - [en](https://longbridge.com/en/quote/SLXN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SLXN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SLXN.US/news.md)
---

# SLXN.US (SLXN.US) — Related News

### [Silexion Therapeutics Announces 1-for-10 Reverse Share Split](https://longbridge.com/en/news/288785467.md)
*2026-06-04T23:57:01.000Z*
> On May 29, 2026, trading for Silexion will commence on a split-adjusted basis at the market open. This strategic adjustm

### [](https://longbridge.com/en/news/287642780.md)
*2026-05-26T13:03:09.000Z*
> Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split.

### [SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX](https://longbridge.com/en/news/287145787.md)
*2026-05-21T02:20:43.000Z*
> In today's market updates, HCW Biologics surged 129% amid concerns over its financial viability. Silexion is set to begi

### [12 Health Care Stocks Moving In Wednesday's Intraday Session](https://longbridge.com/en/news/287099941.md)
*2026-05-20T17:05:59.000Z*
> On Wednesday, HCW Biologics surged 126.4% to $2.4, following its Q1 earnings report. Other gainers included Silexion The

### [Nasdaq Gains 100 Points; Target Earnings Top Views](https://longbridge.com/en/news/287079801.md)
*2026-05-20T13:46:38.000Z*
> U.S. stocks showed mixed results with the Nasdaq up 0.39% and the Dow down 0.03%. Target Corp reported strong earnings, 

### [Silexion Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286771797.md)
*2026-05-18T12:35:11.000Z*
### [Silexion Therapeutics Announces Warrant Inducement Financing Agreement](https://longbridge.com/en/news/286622270.md)
*2026-05-15T22:44:24.000Z*
> Silexion Therapeutics has entered a warrant inducement financing agreement, allowing holders of 1,995,092 existing warra

### [Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary](https://longbridge.com/en/news/286619052.md)
*2026-05-15T21:31:00.000Z*
> Silexion Therapeutics Corp reported a net loss of $2.7M for Q1 2026, with a loss per share of $0.85, compared to a net l

### [Silexion Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286618079.md)
*2026-05-15T21:24:17.000Z*